Deals channel feed – Endpoints News

Deals channel feed

Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal

4 years ago

The antibody discovery team at Twist bets on mouse model player in a boost to its portfolio

4 years ago

Xencor says goodbye to its former lead drug, selling all rights to Lonnie Moulder's new startup

4 years ago

Two of China's top PD-(L)1 players team up on CTLA-4 in $200M deal

4 years ago

Joan Perelló set out 17 years ago to develop a drug. And today he's being rewarded with a $424M biotech buyout

4 years ago

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

4 years ago

Gilead goes all in on its Arcus alliance, paying $725M cash for rights to a slate of cancer drugs. And there's no room for failure

4 years ago

Sanofi inks major AI deal to improve clinical development odds with $270M cash investment

4 years ago

Ahead of expected EU objections, Illumina defends Grail acquisition

4 years ago

In wake of PhII flop, Roche walks away from $350M Covid-19 antiviral pact

4 years ago

A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors

4 years ago

Eye disease specialists venture into M&A with a buyout deal worth up to $126M

4 years ago

J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division

4 years ago

Too much iron? Pharmacosmos is betting $225M on a new potential solution for that

4 years ago

Months after a Merck spinout, Organon continues its string of deals with a $954M buyout package

4 years ago

Genentech teams with little Novome on IBD research, looking to colonized bacteria after a severe setback

4 years ago

Pfizer wagers $1.2B on Biohaven's lead migraine drug — and picks up a next-gen candidate — as marketing wars heat up

4 years ago

J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'

4 years ago

China's Zai Lab spins 2 more licensing deals, including a sudden dive into neuroscience

4 years ago

Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal

4 years ago

Blackstone doubles down on cell therapy, pouring life (and a lot of cash) into a once hot biotech

4 years ago

Fresh off corporate split, bluebird bio plots new hybrid headquarters at Somerville's Assembly Row

4 years ago

PlateletBio announces $75.5M Series B to extend autoimmune cell therapy

4 years ago

More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward

4 years ago

First page Previous page 66 67 686970 71 72 Next page Last page